

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

04 AUG 19 AM 11:11

Lobbying Disclosure Act of 1995 (Section 5) -All Filers Are Required to Complete This Page

TYPE OF REPORT 8. Year 2004 Midyear (January 1-June 30) ☒ OR Year End (July 1-Dec 31) ☐
9. Check if this filing amends a previously filed version of this report ☐
10. Check if this is a Termination Report ☐ >> Termination Date _____ 11. No Lobbying Activities ☐

12. Lobbying Firms	13. Organizations
<p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u> \$62,500.00 </u> <div style="text-align: right; font-size: small;">Income (nearest \$20,000)</div> </p> <p>Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> >> \$ <u> </u> <div style="text-align: right; font-size: small;">Expenses (nearest \$20,000)</div> </p> <p>14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of each method.</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6011 of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(h) of the Internal Revenue Code</p>

Signature



Date 8/15/2004

Printed Name and Title Mark Irion - Chief Executive Officer

F

Registrant Name: The Dutko Group Companies, Inc

Client Name: Biotechnology Research & Devlp Corp.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues

Secure federal appropriations to further biotech research and development

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Irion, Mark	
Simmons, William	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____ Date 07/10/2007

Printed Name and Title Mark Irion - Chief Executive Officer 1